TSCA HEALTH & SAFETY STUDY COVER SHEET

MR 1143

TSCA CBI STATUS:

-CHECK IF THIS PAGE CONTAINS CONFIDENTIAL BUSINESS INFORMATION (CBI)

Clearly mark the confidential information with bracketing and check the box in the appropriate section (☐ *Contains CBI*). Submit a sanitized cover sheet with CBI deleted. Mark the sanitized copy, "Public Display Copy" in the heading.

1.0 SUBMISSION TYPE --*Contains CBI*

☐ 8(d) **X 8(e)** ☐ FYI ☐ 4 ☐ OTHER: Specify 8EHQ-1098-13907

- Intial Submission - X - Follow-up Submission -Final Report Submission

Previous EPA Submission Number or Title if update or follow-up: 8EHQ-97-13907

Docket Number, if any: #

☐ continuation sheet attached

2.1 SUMMARY/ABSTRACT ATTACHED (may be required for 8(e): optional for §4, 8(d) & FYI)

X - YES ☐ NO

2.2 SUBMITTER TRACKING NUMBER OR INTERNAL ID

Cert# P 917006751

98-2-12B

2.3 FOR EPA USE ONLY

3.0 CHEMICAL/TEST SUBSTANCE IDENTITY -*Contains CBI*

CAS#: 111988-49-9

Purity 96+ %

X – Single Ingredient

☐ Commerical/Tech Grade

☐-Mixture

Reported Chemical Name (specify nomenclature if other than CAS name): (Cyanamide, [3-(6-chloro-3-pyridinyl)methyl]-2]thiazolidinylidene]-,

Trade Name: YRC 2894 *Common Name:* Chlornicotinyl

4.0 REPORT/STUDY TITLE - *Contains CBI*

Oncogenicity Study in B6C3F1 Mice (Administration in Food Over 2 Years) Supplemental Submission , Report # 27247A, Study # T9059195

☐ Continuation sheet attached

5.1 STUDY/TSCATS INDEXING TERMS

[CHECK ONE]

HEALTH EFFECTS (HE): X ENVIRONMENTAL EFFECTS (EE): ENVIRONMENTAL FATE (EF):

5.2 STUDY/TSCATS INDEXING TERMS (see instructions for 4 digit codes)

STUDY TYPE: *Other:* Oncogenicity

SUBJECT ORGANISM (HE, EE only): MICE Other:

ROUTE OF EXPOSURE (HE only): *Other:*

VEHICLE OF EXPOSURE (HEonly) Food *Other:*

6.0 REPORT/STUDY INFORMATION ☐ *Contains CBI* X- Study is GLP

Laboratory Bayer Toxicology, Wuppertal, Germany Report/Study Date: 8/18/98

Source of Data/Study Sponsor (if different than submitter) Bayer AG Number of pages 10

☐ continuation sheet attached

7.0 SUBMITTER INFORMATION ☐ *Contains CBI*

Submitter: Donald W. Lamb, Ph.D Title: V. P., Prod. Safety & Reg. Affrs Phone: 412-777-7431

Company Name: Bayer Corporation Company Address: 100 Bayer Road

Pittsburgh, PA 15205-9741

Technical Contact: Donald W. Lamb, Ph.D Submitter Address (if different):

Phone: (412)777-7431

☐ continuation sheet attached

8.0 ADDITIONAL/OPTIONAL STUDY COMMENTS ☐ *Contains CBI*

This supplement is to correct some errors in the original report.

Contains No CBI

☐ continuation sheet attached

Submitter Signature: Donald W Lamb **Date:** 10/1/98

RECEIVED 98 OCT -9 AM 10:47

RECEIVED 98 OCT 15 AM 11:23

RECEIVED 98 OCT 1 AM 11:23

8EHQ-97-13907

89990000016

9.0 CONTINUATION SHEET

TSCA CBI STATUS:

- CHECK IF THIS PAGE CONTAINS CONFIDENTIAL BUSINESS INFORMATION (CBI)

Clearly mark the confidential information with bracketing and check the box in the appropriate section (☐ *Contains CBI*). Submit a sanitized cover sheet with CBI deleted. Mark the sanitized copy, "Public Display Copy" in the heading.

Submitter Tracking Number/Internal ID

P917006751
98-2-12B

CONTINUED FROM COVER SHEET SECTION #____2.1_____

Abstract

Metastatic tumors were accidentally included in Table 15 (Neoplastic changes in animals scheduled for final necropsy). In addition, the designation "(b)" for benign was mistakenly added to stromal cell sarcomas of the uterus and the designation "(M)" for malignant to the astrocytoma in the brain. A corrected table 15 is presented. In Table 16, the number of benign tumors and total tumor number was indicated with 27 and 50. It actually is one less, respectively, since primary tumors in paired organs are counted as one. Other tables are not affected by the resulting changes. There is no effect on the toxicological interpretation of the report for "YRC 2894 Oncogenicity Study in B6C3F1-Mice, Administration in the Food over 2 Years"

SUPPLEMENTAL SUBMISSION TO AC NO. 108358

STUDY TITLE

YRC 2894
Oncogenicity Study in B6C3F1 Mice
(Administration in Food Over 2 Years)

DATA REQUIREMENT

US EPA-FIFRA Guideline No. 83-2

AUTHOR

Dr. U. Wirnitzer

STUDY COMPLETION DATE

Original Report: February 26, 1998
Supplemental Report: August 18, 1998

PERFORMING LABORATORY

BAYER AG
DEPARTMENT OF TOXICOLOGY
Friedrich-Ebert-Strasse 217-233
D-42096 Wuppertal
Germany

LABORATORY PROJECT ID

Bayer AG Report No. 27247 A
Bayer AG Study No. T9059195

STATEMENT OF DATA CONFIDENTIALITY

No claim of confidentiality is made for any information contained in this study on the basis of its falling within the scope of FIFRA Section 10(d)(1)(A), (B), or (C):

BAYER CORPORATION

Dr. J.H. Thyssen: Gusowska for J.H. Thyssen
Vice President, Toxicology

Date: 9-25-98

GLP Compliance Statement

This study was conducted in compliance with the OECD Principles of Good Laboratory Practice (GLP; German version published in: Bundesanzeiger No. 42a, March 2, 1983) and with the Principles of Good Laboratory Practice according to Annex 1 ChemG (Bundesgesetzblatt Part I, July 29, 1994) and meets the FIFRA Good Laboratory Practice Standards (40 CFR Part 160), with the exception that recognized differences exist between the GLP principles/standards of OECD and FIFRA (for instance, authority granted Agency inspectors and certain record retention requirements).

U. Wirnitzer
Dr. U. Wirnitzer
(Study Director)

August 10, 1998
Date

SPONSOR
BAYER AG

L. Machemer
Dr. L. Machemer

August 10, 1998
Date

SUBMITTER

Gresangha for J.H. Thyssen
Dr. J. Thyssen

9-25-98
Date

FLAGGING STATEMENT

I have applied the criteria of 40 CFR 158.34 for flagging studies for potential adverse effects to the results of the attached amendment. The results presented in the amendment to report 27247 neither meet nor exceed any of these criteria.

SUBMITTER
BAYER CORPORATION

Dr. J. Thyssen Gicsangha for J. H. Thyssen

Date 9-25-98

SPONSOR
BAYER AG

Dr. L. Machemer L. Machemer

Date August 10, 1998

STUDY DIRECTOR

Dr. U. Wirnitzer U. Wirnitzer

Date August 10, 1998

TABLE of CONTENTS

	Page
GLP COMPLIANCE STATEMENT	3
QUALITY ASSURANCE STATEMENT	6
ARGUMENT and SIGNATURES	7
CORRECTIONS	8

QUALITY ASSURANCE STATEMENT

Test Substance: YRC 2894
Study No. : T9059195

To the best of my knowledge, the results presented in this amendment and the methods used have been reported correctly.

Quality Assurance Unit
PH-QA-C/GLP, Bayer AG

Date: Aug. 14, 1998

Responsible: _____
(Dr. H. Lehn)

ARGUMENT and SIGNATURES

Accidentally metastatic tumors have been included in Table 15 (Neoplastic changes in animals scheduled for final necropsy). In addition, the designation „(b)" for benign was mistakenly added to stromal cell sarcomas of the uterus and the designation „(m)" for malignant to the astrocytoma in the brain. A correction of Table 15 is presented. In Table 16 the number of benign tumours and total tumour number was indicated with 27 and 50. It actually is one less, respectively, since primary tumours in paired organs are counted as one.

Other tables are not affected by the resulting changes.

There is no effect on the toxicological interpretation of Report No. 27247.

Study Director: U. Wirnitzer (Dr. U. Wirnitzer) August 18, 1998 Date

Head of Section: (Dr. E. M. Bomhard) Aug 18, 1998 Date

CORRECTIONS

Table 15 Neoplastic Changes in Animals Scheduled for Final Necropsy

	Males				Females			
Dose (ppm)	0	30	1250	2500	0	30	1250	2500
BRAIN								
No. examined	50	50	50	50	49	48	50	50
astrocytoma (b)	0	0	0	0	0	1	0	0
LUNGS								
No. examined	50	50	50	50	49	48	50	50
pulmonary adenoma (b)	5	4	5	5	2	1	1	1
pulmonary carcinoma (m)	0	1	0	2	0	0	0	0
DUODENUM								
No. examined	50	49	49	50	49	46	45	47
adenoma (b)	0	0	0	1	0	0	0	0
LIVER								
No. examined	50	50	50	50	49	48	50	50
adenoma, hepatocellular (b)	6	5	6	3	2	0	3	1
carcinoma, hepatocellular (m)	2	2	5	1	0	1	0	0
haemangioma (b)	0	1	0	1	0	0	0	0
haemangiosarcoma (m)	0	1	2	0	0	0	0	0
PANCREAS								
No. examined	50	49	50	50	49	48	50	50
islet cell adenoma (b)	0	0	0	0	0	0	0	1
TESTES								
No. examined	50	50	50	50				
Leydig cell tumor (b)	0	0	0	1				
OVARIES								
No. examined					47	48	49	47
luteoma (b)					0	1	5	5
luteoma, (m)					0	0	0	1
cystadenoma (b)					4	1	1	4
UTERUS								
No. examined					49	48	50	50
stromal polyp (b)					6	1	1	2
glandular polyp (b)					0	1	1	0
adenocarcinoma (m)					0	1	1	1
squamous carcinoma (m)					0	0	1	0
leiomyoma (b)					0	1	1	0
stromal cell sarcoma (m)					1	0	1	2
haemangioma (b)					0	1	1	0
haemangiosarcoma (m)					0	1	0	2

(b) = benign (m) = malignant 0 = no finding

Table 15 (continued)

Neoplastic Changes in Animals Scheduled for Final Necropsy

	Males				Females			
Dose (ppm)	0	30	1250	2500	0	30	1250	2500
PITUITARY GLAND								
No. examined	50	50	50	49	48	47	45	47
adenoma (b)	1	1	1	0	3	6	7	3
carcinoma (m)	0	1	0	0	0	0	0	0
THYROID GLAND								
No. examined	50	50	50	50	49	48	50	50
follicular adenoma (b)	0	0	0	0	0	1	1	0
C-cell adenoma (b)	0	0	0	0	0	0	0	1
ADRENAL GLANDS								
No. examined	49	50	50	50	49	48	50	50
adenoma, subcapsular (b)	1	3	0	0	0	0	0	0
adenoma, cortical (b)	2	1	0	1	0	0	0	0
phaeochromocytoma (b)	0	0	1	0	1	0	0	0
HAEMOLYMPHORETICULAR SYSTEM								
No. examined	7	6	2	4	24	18	16	21
malignant lymphoma (m)	7	4	2	4	18	13	11	14
histiocytic sarcoma (m)	0	1	0	0	7	5	5	7
fibrous histiocytoma (m)	0	1	0	0	0	0	0	1
SPLEEN								
No. examined	50	50	50	50	49	48	50	50
haemangioma (b)	0	0	0	0	1	0	0	0
haemangiosarcoma (m)	1	7	3	1	2	1	0	2
BONE MARROW								
No. examined	50	50	50	50	49	48	50	50
haemangioma (b)	1	0	0	0	0	0	0	0
haemangiosarcoma (m)	0	1	0	0	0	1	0	0
THYMUS								
No. examined	43	45	42	49	46	42	44	44
adenoma (b)	0	0	0	0	1	0	0	0
LYMPH NODES								
No. examined	2	1	0	2	9	12	6	8
haemangioma (b)	0	0	0	0	0	0	0	1
MESENTERIC LYMPH NODE								
No. examined	50	49	49	50	49	44	46	48
haemangioma (b)	0	0	0	0	1	0	1	2
haemangiosarcoma (m)	0	0	0	0	1	0	0	0
SUBMANDIBULAR GLANDS								
No. examined	50	50	50	50	49	47	50	50
sarcoma, nos (m)	0	0	0	0	1	0	0	0

(b) = benign (m) = malignant 0 = no finding

Table 15 (continued)

Neoplastic Changes in Animals Scheduled for Final Necropsy

	Males				Females			
Dose (ppm)	0	30	1250	2500	0	30	1250	2500
HARDERIAN GLANDS								
No. examined	50	50	50	50	49	48	50	50
adenoma (b)	4	2	3	2	0	1	3	1
adenocarcinoma (m)	0	0	0	0	0	1	0	0
MAMMARY GLAND AREA								
No. examined	50	50	50	50	47	46	44	45
adenoma (b)	0	0	0	0	0	1	0	0
adenocarcinoma (m)	0	0	1	0	1	2	1	0
SKIN / SUBCUTANEOUS TISSUE								
No. examined	50	50	50	50	49	48	50	50
fibrosarcoma (m)	0	0	0	0	0	0	2	0
haemangioma (b)	0	1	0	0	0	0	0	0
haemangiosarcoma (m)	0	0	0	0	1	0	0	0
SKELETAL MUSCLE								
No. examined	50	50	50	50	49	48	50	50
rhabdomyosarcoma (m)	0	1	0	0	0	0	0	0
sarcoma, nos (m)	0	0	0	0	0	0	0	1
BONE, VARIOUS								
No. examined	0	1	0	0	2	0	1	1
osteosarcoma (m)	0	0	0	0	1	0	1	0
haemangioma (b)	0	0	0	0	1	0	0	0
BONE (FEMUR)								
No. examined	50	49	49	50	48	48	50	49
haemangiosarcoma (m)	0	1	0	0	1	0	0	0

(b) = benign (m) = malignant 0 = no finding nos = not otherwise specified

Table 16

Number of Tumours

Dose (ppm)	0	30	1250	2500	0	30	1250	2500
Sex	m	m	m	m	f	f	f	f
n	50	50	50	50	50	50	50	50
tumours								
benign	20	18	16	14	22	17	26	22
malignant	10	21	13	8	34	26	23	31
total	30	39	29	22	56	43	49	53

Tumors in paired organs are counted as one primary tumor.